ArticleBrain and behavior2026
Reticulocalbin-2 in the Hippocampus Improves Cognitive Function of Diabetic Mice.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo investigate the underlying mechanism linking diabetes to an increased risk of Alzheimer's disease (AD), specifically by examining the role of reticulocalbin-2 (RCN2) in the hippocampus.
methodsDiabetes-associated cognitive impairment was examined using db/db mice on a C57BL/6J background. Genetic and virus-mediated approaches were employed to achieve hippocampal knockdown, conditional deletion, or overexpression of RCN2. Cognitive function and synaptic integrity were assessed using behavioral, molecular, and histological analyses. In addition, the GSK3β-Tau signaling pathway was analyzed to explore the molecular mechanisms underlying RCN2-mediated synaptic regulation. FINDING: This study reveals that decreased expression of RCN2 in the hippocampus is associated with cognitive impairment. Knockdown of hippocampal RCN2 directly led to cognitive decline and synaptic damage. Mechanistically, RCN2 functions by inhibiting the GSK3β-Tau pathway, thereby delaying synaptic loss. Importantly, overexpression of RCN2 in the hippocampus was found to partially rescue cognitive decline, demonstrating its therapeutic potential for Alzheimer's disease in a diabetic mouse model.
conclusionThe findings suggest that RCN2 is a key neuroprotective protein, and targeting RCN2 could represent a promising therapeutic strategy for neurodegenerative diseases like Alzheimer's, particularly in the context of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.